Leah Price

Leah Price

Auto-generated profile, based on publicly available information

Leah Price

Department of Population Health and

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2010 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
ZMZ. Moodie
Z. Moodie
LPL. Price
L. Price
CGC. Gouttefangeas
C. Gouttefangeas
AMA. Mander
A. Mander
SJS. Janetzki
S. Janetzki
CBCedrik M. Britten
Cedrik M. Britten
No consensus has been reached on how to determine if an immune response has been detected based on raw data from an ELISPOT assay. The goal of this paper is to enable investigators to understand and readily implement currently available methods for response determination. We describe empirical and statistical approaches, identifying the strengths and limitations of each approach to allow readers to rationally select and apply a scientifically sound method appropriate to their specific laboratory setting. Five representative approaches were applied to data sets from the CIMT Immunoguiding Program and the response detection and false positive rates were compared. Simulation studies were also performed to compare empirical and statistical approaches. Based on these, we recommend the use of a non-parametric statistical test. Further, we recommend that six medium control wells or four wells each for both medium control and experimental conditions be performed to increase the sensitivity in detecting a response, that replicates with large variation in spot counts be filtered out, and that positive responses arising from experimental spot counts below the estimated limit of detection be interpreted with caution. Moreover, a web-based user interface was developed to allow easy access to the recommended statistical methods. This interface allows the user to upload data from an ELISPOT assay and obtain an output file of the binary responses.

12 May 2022 in Blood
Verified
Journal Article
Open access
PDF file
JMJohn Mascarenhas
John Mascarenhas
HKHeidi E. Kosiorek
Heidi E. Kosiorek
JPJosef Prchal
Josef Prchal
ARAlessandro Rambaldi
Alessandro Rambaldi
DBDmitriy Berenzon
Dmitriy Berenzon
RHRonald Hoffman
Ronald Hoffman
The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for patients with ET and PV at high risk for vascular complications. Myeloproliferative Disorders Research Consortium 112 was an investigator-initiated, phase 3 trial comparing HU to pegylated IFN-α (PEG) in treatment-naïve, high-risk patients with ET/PV. The primary endpoint was complete response (CR) rate at 12 months. A total of 168 patients were treated for a median of 81.0 weeks. CR for HU was 37% and 35% for PEG (P = .80) at 12 months. At 24 to 36 months, CR was 20% to 17% for HU and 29% to 33% for PEG. PEG led to a greater reduction in JAK2V617F at 24 months, but histopathologic responses were more frequent with HU. Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%). At 12 months of treatment, there was no significant difference in CR rates between HU and PEG. This study indicates that PEG and HU are both effective treatments for PV and ET. With longer treatment, PEG was more effective in normalizing blood counts and reducing driver mutation burden, whereas HU produced more histopathologic responses. Despite these differences, both agents did not differ in limiting thrombotic events and disease progression in high-risk patients with ET/PV. This trial was registered at www.clinicaltrials.gov as #NCT01259856.

14 August 2014 in Blood
Verified
Journal Article
Open access
PDF file
DRDamiano Rondelli
Damiano Rondelli
JGJudith D. Goldberg
Judith D. Goldberg
LILuis Isola
Luis Isola
LPLeah S. Price
Leah S. Price
TSTsiporah B. Shore
Tsiporah B. Shore
RHRonald Hoffman
Ronald Hoffman
Key Points: A high survival rate was seen in primary or secondary MF patients transplanted from matched related donors using the FluMel regimen. FluMel plus ATG in HSCT from unrelated donors for MF patients is associated with an increased risk of graft failure.

25 June 2015 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
SJSylvia Janetzki
Sylvia Janetzki
LPLeah Price
Leah Price
HSHelene Schroeder
Helene Schroeder
CBCedrik M Britten
Cedrik M Britten
MWMarij J P Welters
Marij J P Welters
AHAxel Hoos
Axel Hoos

2 August 2013 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
LMLisa K. McNeil
Lisa K. McNeil
LPLeah Price
Leah Price
CBCedrik M. Britten
Cedrik M. Britten
MJMaria Jaimes
Maria Jaimes
HMHolden Maecker
Holden Maecker
SJSylvia Janetzki
Sylvia Janetzki
Previous results from two proficiency panels of intracellular cytokine staining (ICS) from the Cancer Immunotherapy Consortium and panels from the National Institute of Allergy and Infectious Disease and the Association for Cancer Immunotherapy highlight the variability across laboratories in reported % CD8+ or % CD4+ cytokine‐positive cells. One of the main causes of interassay variability in flow cytometry‐based assays is due to differences in gating strategies between laboratories, which may prohibit the generation of robust results within single centers and across institutions. To study how gating strategies affect the variation in reported results, a gating panel was organized where all participants analyzed the same set of Flow Cytometry Standard (FCS) files from a four‐color ICS assay using their own gating protocol (Phase I) and a gating protocol drafted by consensus from the organizers of the panel (Phase II). Focusing on analysis removed donor, assay, and instrument variation, enabling us to quantify the variability caused by gating alone. One hundred ten participating laboratories applied 110 different gating approaches. This led to high variability in the reported percentage of cytokine‐positive cells and consequently in response detection in Phase I. However, variability was dramatically reduced when all laboratories used the same gating strategy (Phase II). Proximity of the cytokine gate to the negative population most impacted true‐positive and false‐positive response detection. Recommendations are provided for the (1) placement of the cytokine‐positive gate, (2) identification of CD4+ CD8+ double‐positive T cells, (3) placement of lymphocyte gate, (4) inclusion of dim cells, (5) gate uniformity, and 6) proper adjustment of the biexponential scaling. © 2013 International Society for Advancement of Cytometry

18 December 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
RRRaajit K. Rampal
Raajit K. Rampal
JMJohn Mascarenhas
John Mascarenhas
HKHeidi E. Kosiorek
Heidi E. Kosiorek
LPLeah Price
Leah Price
DBDmitriy Berenzon
Dmitriy Berenzon
RHRonald Hoffman
Ronald Hoffman
Myeloproliferative neoplasms (MPN), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to evolve into accelerated and blast-phase disease (MPN-AP/BP), carrying a dismal prognosis. Conventional antileukemia therapy has limited efficacy in this setting. Thus, MPN-AP/BP is an urgent unmet clinical need. Modest responses to hypomethylating agents and single-agent ruxolitinib have been reported. More recently, combination of ruxolitinib and decitabine has demonstrated synergistic in vitro activity in human and murine systems. These observations led us to conduct a phase 1 study to explore the safety of combined decitabine and dose-escalated ruxolitinib in patients with MPN-AP/BP. A total of 21 patients were accrued to this multicenter study. Ruxolitinib was administered at doses of 10, 15, 25, or 50 mg twice daily in combination with decitabine (20 mg/m2 per day for 5 days) in 28-day cycles. The maximum tolerated dose was not reached. The most common reasons for study discontinuation were toxicity/adverse events (37%) and disease progression (21%). Fourteen patients died during study treatment period or follow-up. The median overall survival for patients on study was 7.9 months (95% confidence interval, 4.1-not reached). Among evaluable patients, the overall response rate by protocol-defined criteria (complete remission with incomplete count recovery + partial remission) was 9/17 (53%) and by intention-to-treat analysis was 9/21 (42.9%). The combination of decitabine and ruxolitinib was generally well tolerated by patients with MPN-AP/BP and demonstrates potentially promising clinical activity. A phase 2 trial evaluating the efficacy of this combination regimen is ongoing within the Myeloproliferative Disorder Research Consortium.